M&A Deal Summary

Medix Biochemica Acquires ViroStat

On November 10, 2023, Medix Biochemica acquired life science company ViroStat

Acquisition Highlights
  • This is Medix Biochemica’s 2nd transaction in the Life Science sector.
  • This is Medix Biochemica’s 1st transaction in the United States.
  • This is Medix Biochemica’s 1st transaction in Maine.

M&A Deal Summary
Date 2023-11-10
Target ViroStat
Sector Life Science
Buyer(s) Medix Biochemica
Deal Type Add-on Acquisition

Target

ViroStat

Westbrook, Maine, United States
ViroStat is a primary manufacturer of infectious disease antibodies and antigens, supplying manufacturers and researchers. ViroStat was founded in 1985 and is based in Westbrook, Maine.

Search 201,771 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Medix Biochemica

Espoo, Finland
Category Company
Founded 1985
Sector Life Science
Employees220
Revenue 55M EUR (2021)
DESCRIPTION

Medix Biochemica develops, manufactures, and markets critical raw materials including antibodies, antigens, and biologicals for IVD companies worldwide. Medix Biochemica was formed in 1985 and is based in Espoo, Finland.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
State (Maine) 1 of 1
Country (United States) 1 of 1
Year (2023) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-07-13 Diaclone

Besancon, France

Diaclone provides expertise in the fields of inflammation, oncology, and immunology. The company offers best-in-class monoclonal antibodies, high-quality ELISA and ELISPOT kits as well as custom services ranging from immunoassay kit development to new antibody discovery using hybridoma and phage display technologies to a broad range of IVD, life science, and pharma customers. Diaclone was formed in 1986 and is based in Besancon, France.

Buy -
Mergr

Product

Company

Legal